Wright Medical Group N.V. raised sales guidance for the full year of 2018 and provided earnings guidance for the full year of 2019. Based on the strong performance of the business in the third quarter to date, the company raised and narrowed its full-year 2018 net sales guidance, excluding the impact of the Cartiva acquisition to approximately $812 million to $822 million, from its previous guidance of approximately $808 million to $820 million. 

Assuming a close of the transaction in 2018, the company anticipates the acquisition to increase 2019 net sales by approximately $47 million and non-GAAP adjusted EBITDA from continuing operations by approximately $20 million, which the company anticipates will be approximately 100 basis points accretive to the company's pro forma net sales growth rate (on a constant currency basis) and approximately 100 basis points accretive to non-GAAP adjusted EBITDA margin from continuing operations.